• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 440794 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416779970 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416779970 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Bid Up Shares of Rigel Pharmaceuticals, Up 1.8%

Published on Tue, 02/12/2013 - 13:18
By Robert Cotter

Rigel Pharmaceuticals (NASDAQ:RIGL), a company whose shares are moving quickly, is trading 1.8% higher to $6.62. The S&P is currently trading 0.2% higher to 1,520 and the Dow Jones Industrial Average is trading 0.3% higher to 14,016.

There is potential upside of 54.4% for shares of Rigel Pharmaceuticals based on a current price of $6.62 and an average consensus analyst price target of $10.22. The stock should run into initial resistance at its 50-day moving average (MA) of $6.97 and subsequent resistance at its 200-day MA of $8.58.

Over the past year, Rigel Pharmaceuticals has traded in a range of $5.37 to $11.44 and is now at $6.62, 23% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.2% while the 50-day MA has declined 1.5%.

Rigel Pharmaceuticals, Inc. discovers and develops novel, small molecule drugs in four lead product development programs: allergy/asthma, autoimmune disorders, hepatitis C, and cancer. The Company's first product candidate, R112, for allergic rhinitis is already in clinical testing. Rigel plans to begin clinical trials with the three additional drug candidates over the next 12 months.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Post Earnings Update: International Pape...

When International Paper (NYSE:IP) reported earnings two weeks ago on November 4th, 201 ...

Protective Life Earnings Review: 19 Days...

Two weeks ago on November 3rd, 2014 Protective Life (NYSE:PL) reported earnings and ana ...

Earnings Look Back: Estee Lauder Is Up 1...

18 days ago, on November 4th, 2014, Estee Lauder (NYSE:EL) reported its earnings. Anal ...

Delek US Holdings Earnings Review: 17 Da...

When Delek US Holdings (NYSE:DK) reported earnings two weeks ago on November 5th, 2014, ...

Earnings Look Back: Stifel Financial Is ...

When Stifel Financial (NYSE:SF) reported earnings two weeks ago on November 6th, 2014, ...

Post Earnings Update: Dean Foods Has Cli...

A week ago on November 10th, 2014 Dean Foods (NYSE:DF) reported earnings and analysts, ...

Earnings Look Back: CF Industries Is Up ...

When CF Industries (NYSE:CF) reported earnings two weeks ago on November 5th, 2014, ana ...

Spectra Energy Earnings Hindsight: Up 0....

When Spectra Energy (NYSE:SE) reported earnings 17 days ago on November 5th, 2014, anal ...